[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fICecHIorFBbFYgo0berKFGTz0PIYeEzi17faxJedqNc":8,"$fYA_mFZgpyRCsl-lZqUkd_QbHzryG0H_3sPg-gHuxJpY":55,"$ffnR0hvwTkZ-i79BUmvbzG3tnAJYQWUuvwaF8ZVlz6PQ":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},65624,863254,[],"https://ystcdn.venuertc.com/medical/ystApp/Dlmj9URvs7gXdepZpARivDbqwZwkg06p.png","朱永亮","龙口南山养生谷肿瘤医院","放射科","住院医师",397,0,"肝癌晚期治疗新选择：贝伐珠单抗与信迪利单抗联合疗法用药全指南","","https://ystcdn.venuertc.com/venue/AI/62081b8b-0f5d-48ea-9815-126cb8ea3c41.jpg","\u003Cdiv class=\"medguide-root\">\n  \u003Ch2 id=\"material_title\" class=\"medguide-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">肝癌晚期治疗新选择：贝伐珠单抗与信迪利单抗联合疗法用药全指南\u003C/h2>\n  \u003Cdiv class=\"medguide-intro\">\n    \u003Cp>说起来，针对肿瘤晚期的新型用药越来越多，贝伐珠单抗和信迪利单抗这种联合疗法已经逐步成为临床上的重要选择。作为两种生物制剂类药物，它们的作用机制和使用方式却大不一样。本文将系统梳理这两种药品在使用过程中必须注意的7大关键细节，包括给药方法、储存条件、不良反应、特殊人群用药等，让您真正做到安全规范用药。 👩‍⚕️🧑‍⚕️\u003C/p>\n  \u003C/div>\n\n  \u003Csection class=\"medguide-section medguide-bg1\">\n    \u003Ch2 class=\"medguide-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">1. 药品成分与剂型特点\u003C/h2>\n    \u003Cdiv class=\"medguide-section-content\">\n      \u003Cul>\n        \u003Cli>\u003Cstrong>贝伐珠单抗：\u003C/strong>是一种人源化单克隆抗体，主要针对血管内皮生长因子A（VEGF），以注射液为主，常见规格有100mg/4ml和400mg/16ml两种。\u003C/li>\n        \u003Cli>\u003Cstrong>信迪利单抗：\u003C/strong>同样属于人源化单克隆抗体（IgG4κ型），靶向PD-1受体，常见剂型为100mg/瓶的注射用溶液，需用生理盐水稀释静脉给药。\u003C/li>\n      \u003C/ul>\n      \u003Cp class=\"medguide-case-ex\">实际案例：临床中，患者多按照体重和实际情况，由医生选择合适规格的注射药液。切记不能私自换药或更改规格。\u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"medguide-section medguide-bg2\">\n    \u003Ch2 class=\"medguide-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">2. 药物作用机制简析\u003C/h2>\n    \u003Cdiv class=\"medguide-section-content\">\n      \u003Cp>\n        贝伐珠单抗主要通过阻断肿瘤生长所需的新生血管生成，简单说就是“切断供给线”，减少肿瘤细胞的营养供应（Hurwitz et al., 2004）。信迪利单抗则通过解除免疫系统中的抑制机制，激活身体的T细胞攻击异常细胞（Wang et al., 2019）。两药联合能同时“断供”与“动员”，增强整体治疗效力。\n      \u003C/p>\n      \u003Cul>\n        \u003Cli>\u003Cstrong>贝伐珠单抗：\u003C/strong>专注于抑制血管新生。\u003C/li>\n        \u003Cli>\u003Cstrong>信迪利单抗：\u003C/strong>提升免疫系统杀伤能力。\u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"medguide-section medguide-bg3\">\n    \u003Ch2 class=\"medguide-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">3. 正确用药时间与给药方式\u003C/h2>\n    \u003Cdiv class=\"medguide-section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>贝伐珠单抗：\u003C/strong>\n          \u003Cul>\n            \u003Cli>规范采用静脉滴注，每次输液15-90分钟。\u003C/li>\n            \u003Cli>建议每2-3周为一周期，周期和剂量由专科医生根据体重与耐受性设定。\u003C/li>\n            \u003Cli>首次用药应在有急救条件的医院进行，主要防备罕见的过敏反应。\u003C/li>\n          \u003C/ul>\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>信迪利单抗：\u003C/strong>\n          \u003Cul>\n            \u003Cli>同样通过静脉滴注给药，每次输注约需30-60分钟。\u003C/li>\n            \u003Cli>常规为每3周一次；不建议自行调整注射间隔。\u003C/li>\n          \u003C/ul>\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp class=\"medguide-tip\">\u003Cspan>✅ 正确做法：\u003C/span>输注当天需监测血压、体温等生命体征，输注前后避免剧烈运动、饮酒或驾驶。\u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"medguide-section medguide-bg4\">\n    \u003Ch2 class=\"medguide-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">4. 药物相互作用需格外注意\u003C/h2>\n    \u003Cdiv class=\"medguide-section-content\">\n      \u003Cp>贝伐珠单抗和信迪利单抗合用时，应全面告知医生所有在用的药品，包括口服药、中草药以及保健品，以避免潜在相互作用。\u003C/p>\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>贝伐珠单抗：\u003C/strong>\n          \u003Cul>\n            \u003Cli>合并铂类、氟尿嘧啶等药物时，容易出现不良反应叠加。\u003C/li>\n            \u003Cli>避免同时使用抗血小板药、抗凝剂，否则出血风险增加。\u003C/li>\n          \u003C/ul>\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>信迪利单抗：\u003C/strong>\n          \u003Cul>\n            \u003Cli>慎与免疫抑制剂、激素类药物联用，以免免疫效力降低或感染风险提升。\u003C/li>\n            \u003Cli>不建议自行添加提升免疫的药品。\u003C/li>\n          \u003C/ul>\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp class=\"medguide-tip\">\u003Cspan>建议：\u003C/span>每次调整用药或新开药品前，都要和主管医生核实全部药物清单。\u003C/p>\n      \u003Cp class=\"medguide-case-ex\">临床数据显示，联合用药时约有30%的患者出现高血压或蛋白尿（Zhu et al., 2020）。\u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"medguide-section medguide-bg5\">\n    \u003Ch2 class=\"medguide-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">5. 常见不良反应及自我监护\u003C/h2>\n    \u003Cdiv class=\"medguide-section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>贝伐珠单抗：\u003C/strong>\n          \u003Cul>\n            \u003Cli>高血压、蛋白尿、轻中度出血倾向较多见，如出现异常头痛、泡沫尿应及时就诊。\u003C/li>\n            \u003Cli>偶发口腔溃疡与皮肤轻度裂口。\u003C/li>\n          \u003C/ul>\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>信迪利单抗：\u003C/strong>\n          \u003Cul>\n            \u003Cli>皮疹、乏力、食欲减退较常见。\u003C/li>\n            \u003Cli>还可能引起甲状腺功能变化或免疫相关炎症（如轻度肺炎、结肠炎等）。\u003C/li>\n          \u003C/ul>\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp class=\"medguide-tip\">🔍 \u003Cspan>正确做法：\u003C/span>用药期间留心自身有无持续性头痛、明显乏力、皮肤异常等表现。如出现持续高热、气促、严重皮疹，要第一时间停药就医。\u003C/p>\n      \u003Cp class=\"medguide-case-ex\">曾有患者因蛋白尿经减量处理2周后逐步恢复，据临床数据严重不良反应发生率约2%-6%（Wang et al., 2019）。\u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"medguide-section medguide-bg6\">\n    \u003Ch2 class=\"medguide-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">6. 用药禁忌与特殊人群用药调整\u003C/h2>\n    \u003Cdiv class=\"medguide-section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>贝伐珠单抗禁忌：\u003C/strong>\n          \u003Cul>\n            \u003Cli>对药品成分过敏者严禁使用。\u003C/li>\n            \u003Cli>有未愈合手术创面、近期有严重出血病史者不可用药。\u003C/li>\n            \u003Cli>尚未控制的高血压不宜用药。\u003C/li>\n          \u003C/ul>\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>信迪利单抗禁忌：\u003C/strong>\n          \u003Cul>\n            \u003Cli>既往对本品或同类药品重度过敏史者禁用。\u003C/li>\n            \u003Cli>如曾因免疫异常而有严重药物副作用史者，需慎重评估。\u003C/li>\n          \u003C/ul>\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>特殊人群：\u003C/strong>\n          \u003Cul>\n            \u003Cli>老年人：因代谢减弱，由医生根据体能调整剂量。\u003C/li>\n            \u003Cli>儿童：目前未明确批准，只有严格评估后才考虑特殊用药。\u003C/li>\n            \u003Cli>孕妇及哺乳期：\u003Cspan>禁用\u003C/span>，并需停药6月后才可备孕。\u003C/li>\n            \u003Cli>肝肾功能减退者：由专科医生权衡是否减量或延长给药间隔。\u003C/li>\n          \u003C/ul>\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp class=\"medguide-tip\">特别提醒：如突发全身过敏、严重高热或无法解释的新症状，须停止用药，并尽快入院处理。\u003C/p>\n      \u003Cp class=\"medguide-case-ex\">有过因手术创面未愈合而延迟贝伐珠单抗输注2周，顺利避免相关并发症。\u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"medguide-section medguide-bg7\">\n    \u003Ch2 class=\"medguide-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">7. 储存要求、有效期与紧急处理\u003C/h2>\n    \u003Cdiv class=\"medguide-section-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cstrong>贝伐珠单抗：\u003C/strong>需2-8°C冷藏，避免冷冻和暴晒。开封未用完的部分必须立即丢弃，\u003Cspan>不可\u003C/span>下次再用。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>信迪利单抗：\u003C/strong>2-8°C冷藏且避光保存。稀释后的溶液应在4小时内用完，剩余部分一律弃置。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>过期或异常储存药品的处理：\u003C/strong>交回医院或药房，不能自行处置或继续使用。\n        \u003C/li>\n        \u003Cli>\n          \u003Cstrong>漏服、超量：\u003C/strong>如某次漏掉输注，立即联系主治医生，按医嘱调整，无需自行补发剂量。若不慎超量，需到医院接受专业监护，没有专门的解毒药。\u003C/li>\n      \u003C/ul>\n      \u003Cp class=\"medguide-tip\">正确做法：家用冰箱冷藏要避免频繁开关，防止药品活性下降。不要自行拖延输注或私自增加剂量。\u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"medguide-section medguide-bg8\">\n    \u003Ch2 class=\"medguide-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">8. 用药经验小结与安全提示\u003C/h2>\n    \u003Cdiv class=\"medguide-section-content\">\n      \u003Col>\n        \u003Cli>所有用药过程必须严格遵医嘱，按时按量，绝不擅自调整方案。\u003C/li>\n        \u003Cli>联合用药时尤其要高度警惕不良反应，如高血压、蛋白尿、持续发热等，一旦出现异常，早联系医生。\u003C/li>\n        \u003Cli>详细告知医生当前所有用药和补充剂，避免相互作用风险。\u003C/li>\n        \u003Cli>没有用完或过期的药物必须妥善处理，确保家人和环境安全。\u003C/li>\n      \u003C/ol>\n      \u003Cp>掌握这几条经验，不仅能减轻药物带来的风险，也能帮助提升整体治疗成效。\u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"medguide-section medguide-bg9\">\n    \u003Ch2 class=\"medguide-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">9. 核心文献来源\u003C/h2>\n    \u003Cdiv class=\"medguide-section-content medguide-refs\">\n      \u003Col>\n        \u003Cli>Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., ... & Kabbinavar, F. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. \u003Cem>New England Journal of Medicine\u003C/em>, 350(23), 2335-2342.\u003C/li>\n        \u003Cli>Wang, Y., Wang, H., Yao, H., Li, C., Fang, J. Y., & Xu, J. (2019). Regulation of PD-L1: Emerging routes for targeting tumor immune evasion. \u003Cem>Frontiers in Pharmacology\u003C/em>, 10, 964.\u003C/li>\n        \u003Cli>Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., ... & Kudo, M. (2020). Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. \u003Cem>Lancet Oncology, 19\u003C/em>(7), 940-952.\u003C/li>\n        \u003Cli>Genentech. (2021). Avastin (bevacizumab) [Prescribing Information]. South San Francisco, CA: Genentech, Inc.\u003C/li>\n        \u003Cli>Yuan, J., Yu, F., Wang, W., Jiang, J., & Xu, Q. (2021). Application of immune checkpoint inhibitors in pediatric tumors. \u003Cem>Frontiers in Oncology\u003C/em>, 11, 639398.\u003C/li>\n      \u003C/ol>\n    \u003C/div>\n  \u003C/section>\n\u003C/div>\n\n\n\u003Cstyle>\n.medguide-root { font-family: 'Helvetica Neue', Helvetica, Arial, 'PingFang SC', 'Microsoft YaHei', sans-serif; color: #232323; background: #f5f8fa; padding: 0 30px 50px 30px; max-width: 820px; margin:0 auto; box-sizing: border-box; }\n.medguide-title { font-size: 2.2em; color: #26344b; letter-spacing: 1px; font-weight: bold; text-align: left; margin: 40px 0 25px 0; }\n.medguide-intro { background: linear-gradient(90deg, #ddecfa 0, #faf6ed 100%); border-left: 6px solid #6cbbe3; padding:18px 26px; border-radius: 0 10px 10px 0; margin: 0 0 35px 0; font-size: 1.1em;}\n.medguide-section { margin-bottom: 35px; border-radius: 18px; box-shadow: 0 2px 5px rgba(99,133,176,0.06);}\n.medguide-section-title { \n  font-size: 1.42em; \n  font-weight: bold; \n  color: #22537b; \n  margin-top: 0;\n  margin-bottom: 15px; \n  letter-spacing: 1px;\n  padding:22px 28px 8px 32px;\n  border-radius:18px 18px 0 0;\n}\n.medguide-section-content {\n  font-size: 1.06em;\n  padding: 12px 34px 20px 34px;\n  line-height: 1.9em;\n}\n.medguide-bg1 {background: linear-gradient(95deg, #e2f4fd 60%, #f5f8fa 100%);}\n.medguide-bg2 {background: linear-gradient(90deg, #f2ffef 60%, #f5f8fa 100%);}\n.medguide-bg3 {background: linear-gradient(90deg, #fffde2 60%, #f5f8fa 100%);}\n.medguide-bg4 {background: linear-gradient(90deg, #eaf2fa 55%, #f5f8fa 100%);}\n.medguide-bg5 {background: linear-gradient(85deg, #e9faff 45%, #f5f8fa 100%);}\n.medguide-bg6 {background: linear-gradient(100deg, #f8effb 80%, #f5f8fa 100%);}\n.medguide-bg7 {background: linear-gradient(95deg, #eaf4ea 65%, #f5f8fa 100%);}\n.medguide-bg8 {background: linear-gradient(110deg, #f7fbe9 85%, #f5f8fa 100%);}\n.medguide-bg9 {background: linear-gradient(110deg, #e2eaf1 75%, #f5f8fa 100%);}\n.medguide-tip {background: rgba(79,161,211,0.08); color: #2c609e; border-left: 4px solid #6cbbe3; padding:8px 16px; border-radius: 0 8px 8px 0; margin:17px 0 10px 0; font-size: 1.02em;}\n.medguide-tip span {font-weight:bold;}\n.medguide-case-ex {color: #666f7a; border-left:3px solid #e2bf66; background:rgba(255,242,195,0.09); padding-left:14px; margin:12px 0 7px 0; font-size: 1.01em;}\n.medguide-refs {font-size:0.98em;}\n.medguide-section-content ul,\n.medguide-section-content ol {margin: 12px 0 15px 15px;}\n.medguide-section-content li {margin-bottom: 7px;}\n.medguide-section-content ul li strong {color:#22537b;}\n@media (max-width:750px){\n  .medguide-root {padding:10px 7px 45px 7px;}\n  .medguide-title {font-size:1.4em;}\n  .medguide-section-content {padding:9px 6px 17px 14px;}\n  .medguide-section-title {padding:18px 10px 6px 16px;}\n}\n\u003C/style>\n\n","\u003Cdiv class=\"medguide-root\">\n  \u003Ch2 id=\"material_title\" class=\"medguide-title\" style=\"color: rgb(44, 6",505,"2025-09-04 10:07:52","肝癌, 贝伐珠单抗, 信迪利单抗, 联合疗法, 不良反应, 用药指南, 安全用药, 新型治疗","了解贝伐珠单抗与信迪利单抗联合用药的新选择，掌握关键注意事项与不良反应，提升肝癌晚期患者的治疗安全性和效果。","2025-09-08 11:38:46",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]